ASH 24 Posters
GTC presented abstracts at ASH 2024 GTC’s posters from 2024 Convention of American Society of Hematology are now available to be downloaded. Please reach out
GTC presented abstracts at ASH 2024 GTC’s posters from 2024 Convention of American Society of Hematology are now available to be downloaded. Please reach out
Just published in The Journal of Liquid Biopsy Liquid biopsy for evaluating mutations and chromosomal aberrations in cerebrospinal fluid from patients with primary or metastatic
Maher Albitar, Ahmad Charifa, Sally Agersborg, Andrew Pecora, Andrew Ip, Andre Goy Abstract: Most of the current utilization of liquid biopsy (LBx) is based on
New publication in New England Journal of Medicine for Genomic Testing Cooperative (GTC). GTC work was in collaboration with Dana-Faber cancer Institute/Harvard Medical School, Georgetown
New Paper in Journal of Clinical Pathways GTC has participated in a new paper titled: Bringing Value to Health Care. Read the paper as it
GTC presented abstracts at ASCO 2024 GTC’s posters from 2024 Convention of American Society of Clinical Oncology are now available to be downloaded. Please reach
Acute graft-versus-host disease (aGvHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), occurring to some degree in over 50% of patients and being a direct cause of death in about 20% of patients. This complication occurs even despite a better understanding of donor selection and GvHD prophylaxis regimens. aGvHD is a complex event in which multiple contributing factors are involved. We performed RNA transcriptome analysis of 1408 genes in bone marrow samples obtained before and after transplantation using machine learning to predict the risk of aGvHD and post-transplant survival for a cohort of patients undergoing HSCT. Differential gene expression identified several signaling pathways in the bone marrow microenvironment that may be major regulators of the complex biology of GvHD, and identified targets of intervention to ameliorate the risk of aGvHD and improve patient survival.
Introducing a novel liquid biopsy approach combining cfRNA and cfDNA sequencing. Our findings demonstrate superior mutation detection with cfRNA, while cfDNA excels in identifying chromosomal aberrations. Elevated cfRNA biomarkers correlate with tumor types, aiding diagnosis. Machine learning predicts cancer types accurately. Host immune response analysis through cfRNA ratios reveals distinct patterns in cancer patients. This integrated approach holds promise for predicting genomic abnormalities and cancer diagnosis
This study delves into the potential of RNA profiling, specifically examining HER2, ESR1, and AR mRNA levels, providing nuanced insights for precise therapeutic interventions and outcome predictions in breast cancer.
This study delves into the potential of RNA profiling, specifically examining HER2, ESR1, and AR mRNA levels, providing nuanced insights for precise therapeutic interventions and outcome predictions in breast cancer.